CompletedNCT01331304
Lithium Compared With Quetiapine for People Living With Bipolarity
About this title
Comparative Effectiveness Study for Bipolar Disorder
Read the official source — NCT01331304Medication studyAges 18–68United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 68 years.
- Listed locations
- Birmingham and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 482
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 68 Years
- Official registry ID
- NCT01331304
- Official title
Show the full official title
Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Stanford · Boston
8 more locations
- Ann Arbor
- New York
- Cleveland
- Mason
- Philadelphia
- Pittsburgh
- Nashville
- San Antonio
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including lithium and Quetiapine.
Who was this study for?
Listed age limits: 18 years to 68 years.
